My research interests are focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and approaches for risk prediction, population stratification, targeted screening, cancer prevention and cost-effectiveness analyses.
A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol (2019). PMID: 31580391
Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation-testing in unselected general-population women. J Natl Cancer Inst (2018); 110(7):714-725. PMID: 29361001
Cost effectiveness of population screening for BRCA mutations in Ashkenazi-Jewish women compared to family-history based testing. J Natl Cancer Inst (2015); 107(1):380. PMID: 25435542
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomised controlled trial. J Natl Cancer Inst (2015); 107(1):379. PMID: 25435541
My research is focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and precision medicine approaches for risk prediction, population stratification, targeted screening, cancer prevention (including surgical prevention) and management of familial gynaecological cancer. I have a keen research interest in health economic issues related to these areas.
I am Chief Investigator (CI) on PROTECT (PROTECT: Population based Germline testing for Early detection and Cancer Prevention); PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) trial; DETECT-2 (Direct to Patient testing at Cancer diagnosis for Precision Prevention) study; PRESCORES (Prevention of endometrial cancer: Utility scores of risk-reducing strategies); JHCR (Jewish Hereditary Cancer Research); PROMISE Feasibility study (pilot general population testing and personalised ovarian cancer risk prediction study); SIGNPOST (SystematIc GeNetic testing for Personalised Ovarian cancer Therapy) study and RRESDO (study evaluating attitudes towards early salpingectomy) studies; Co-PI of GCaPPS trial (population based BRCA testing RCT in the Jewish population); Co-Lead for UKCOGS (UK COVID and Gynaecological Cancer Study); Co-lead for SURAKSHA- South Asian Breast Cancer Risk Prediction, Genetic testing & Health Management programme. I have worked on ovarian cancer screening trials (UKCTOCS, UKFOCSS and ALDO).
Academic Roles (select):
Clinical Roles (select):
Other roles:
Clinical Interests: Ovarian cancer radical debulking surgery, Sentinel node biopsy, Management of women at high risk of gynaecological cancer
Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis. Gaba F, Blyuss O, Tan A et al. Cancers (Basel) (2023) 15(2)
https://www.ncbi.nlm.nih.gov/pubmed/36900415
Cost-Effectiveness of Genetic Testing Strategies for Breast Cancer Oxley S, Wei X, Sideris M et al. (2023) (10) 113-126
Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UK Oxley S, Kalra A, Sideris M et al. Cancers (2023) 15(7)
Association of Hospital Surgical Volume With Survival in Early-Stage Cervical Cancer Treated With Radical Hysterectomy Bizzarri N, Dostálek L, Van Lonkhuijzen LRCW et al. Obstetrics and Gynecology (2023) 141(7) 207-214
Prioritizing the detection of rare pathogenic variants in population screening Lacaze P, Manchanda R, Green RC Nature Reviews Genetics (2023) (7)
Variation in outcome reporting in studies of fertility-sparing surgery for cervical cancer: A systematic review Yong N, Cooper N, Yorke S et al. BJOG: An International Journal of Obstetrics and Gynaecology (2023) 130(7) 163-175
Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review Wei X, Oxley S, Sideris M et al. Cancers (2022) 14(7)
Quality of Life after Risk-Reducing Hysterectomy for Endometrial Cancer Prevention: A Systematic Review Oxley S, Xiong R, Wei X et al. Cancers (2022) 14(7)
UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 Hanson H, Kulkarni A, Loong L et al. Journal of Medical Genetics (2022) (10) jmg-2022-108898
Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative) Gaba F, Ash K, Blyuss O et al. International Journal of Gynecologic Cancer (2022) 32(13) 1606-1610
For additional publications, please click hereAcademic Clinical Lecturer
Senior Research Fellow
Clinical Trials Coordinator
PhD Students
Honorary Research Fellows
I was appointed as Professor of Gynaecological Oncology at Wolfson Institute of Population Health, Queen Mary University of London in Sep 2019. I joined Barts Cancer Institute, Queen Mary, as a Clinical Senior Lecturer in June 2015. I have worked as a consultant Gynaecological Oncologist at Barts Health NHS Trust from June 2015. From 2014- 2015 I worked as a Locum Consultant Gynaecological Oncologist at Barts Health and Honorary Senior Lecturer at University College London, UK. I completed a PhD in gynaecological oncology at UCL, followed by a NIHR ACL Fellowship and subspecialty training in gynaecological oncology from UCLH and Bart's Hospital.
I am Co-Lead for Cancer Prevention Unit, Wolfson Institute of Population Health, Queen Mary; and Co-Lead for Cancer Prevention (Theme-1), CRUK Barts Centre. I was awarded an NHS Innovation Accelerator Fellowship in March 2019. I am Chief Investigator (CI) on PROTECT (PROTECT: Population based Germline testing for Early detection and Cancer Prevention); PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) trial; DETECT-2 (Direct to Patient testing at Cancer diagnosis for Precision Prevention) study; PRESCORES (Prevention of endometrial cancer: Utility scores of risk-reducing strategies); JHCR (Jewish Hereditary Cancer Research); PROMISE Feasibility study (pilot general population testing and personalised ovarian cancer risk prediction study); SIGNPOST (SystematIc GeNetic testing for Personalised Ovarian cancer Therapy) study and RRESDO (study evaluating attitudes towards early salpingectomy) studies; Co-PI of GCaPPS trial (population based BRCA testing RCT in the Jewish population); Co-Lead for UKCOGS (UK COVID and Gynaecological Cancer Study); Co-lead for SURAKSHA- South Asian Breast Cancer Risk Prediction, Genetic testing & Health Management programme. I have worked on ovarian cancer screening trials (UKCTOCS, UKFOCSS and ALDO).
I lead the Barts Health Women’s Precision Prevention Service, Chair the London Cancer High Risk Gynaecological Cancer MDT, Member National Cancer Programme Early Diagnosis Task & Finish group, Topic Advisor (Clinical Lead) for the NICE Guideline on Familial Ovarian Cancer, and Clinical Lead for Gynaecological Cancer North Thames GLH. I am scientific advisor to BRCA Umbrella and GO Girls, Chair the Independent Advisory Committee of the Mermaid Project (Demark) and serve on number of oversight committees.
I am actively involved in gynaecological oncology training issues. I helped develop and establish ENYGO (European Network of Young Gynaecological Oncologists) from its inception and have led/undertaken a number of initiatives for European and International trainees in gynaecological oncology. I have served as the president of the European Network of young Gynaecological Oncologists (ENYGO) and a member of the European Society of Gynaecological Oncology (ESGO) council (2011-2013). I am the Integrated Academic Training Programme Director and lead for the RCOG Advanced Professional Module (APM) in Clinical Research for London Specialty School of Obstetrics & Gynaecology, Health Education England. I am the deputy director of the Barts Health RCOG gynaecological oncology training programme and Mentor for the IGCS Gynecologic Oncology Global Curriculum & Mentorship Program.
Previous posts
Education & Qualifications